Literature DB >> 1194848

Interactions of C-reactive protein with the complement system. III. Complement-dependent passive hemolysis initiated by CRP.

.   

Abstract

Interactions of CRP with various substrates in the presence of human serum have been shown to result in efficient activation of C components C1-C5. We now report the ability of CRP to initiate C-dependent hemolysis. For this purpose CRP was isolated by affinity chromatography using pneumococcal CPS and gel filtration; its purity was established by several criteria. Erythrocytes were coated with CPS (E-CPS) and passively sensitized with CRP. C-dependent lysis of these cells was observed upon the addition of suitably absorbed human serum, and the efficiency of hemolysis compared favorably with that initiated by rabbit IgG anti-CPS antibody. CRP also sensitized E-CPS for lysis by guinea pig C; partial lysis was seen when C4-deficient guinea pig serum was used, suggesting that CRP also shares with antibody the ability of CRP to fully activate the C system and provide further evidence for a role for CRP similar to that of antibody in the initiation and modulation of inflammatory reactions via the complete system.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1194848      PMCID: PMC2189960          DOI: 10.1084/jem.142.5.1065

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Antibody response to phosphorylcholine in vitro. I. Studies on the frequency of precursor cells, average clone size and cellular cooperation.

Authors:  H Cosenza; J Quintáns; I Lefkovits
Journal:  Eur J Immunol       Date:  1975-05       Impact factor: 5.532

2.  Isolation of C-reactive proteins of man, monkey, rabbit and dog by affinity chromatography on phosphorylated cellulose.

Authors:  R F Riley; M K Coleman
Journal:  Clin Chim Acta       Date:  1970-11       Impact factor: 3.786

3.  Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria.

Authors:  C O Kindmark
Journal:  Clin Exp Immunol       Date:  1971-06       Impact factor: 4.330

4.  Structural and immunological studies on the pneumococcal C polysaccharide.

Authors:  E C Gotschlich; T Y Liu
Journal:  J Biol Chem       Date:  1967-02-10       Impact factor: 5.157

5.  Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. II. Evidence for involvement of C1 and components of the alternate complement pathway.

Authors:  J E May; M M Frank
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

6.  Affinity labeling of a phosphorylcholine binding mouse myeloma protein.

Authors:  B Chesebro; H Metzger
Journal:  Biochemistry       Date:  1972-02-29       Impact factor: 3.162

7.  C-reactive protein: a molecule composed of subunits.

Authors:  E C Gotschlich; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1965-08       Impact factor: 11.205

8.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

9.  Hapten binding studies on mouse IgA myeloma proteins with antibody activity.

Authors:  A Sher; H Tarikas
Journal:  J Immunol       Date:  1971-05       Impact factor: 5.422

10.  Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera.

Authors:  J Siegel; R Rent; H Gewurz
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  19 in total

1.  Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness.

Authors:  K M Chiu; R F Mortensen; A P Osmand; H Gewurz
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

Review 2.  Oral ulceration and Behçet's syndrome.

Authors:  T Lehner
Journal:  Gut       Date:  1977-06       Impact factor: 23.059

3.  The relationship of a serum protein, C1t, to a common nonfibrillar constituent of amyloid (P component) as revealed by immunohistochemical studies.

Authors:  A Katz; J Weicker-Thorne; R H Painter
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

4.  C-reactive protein-mediated complement activation in polymyalgia rheumatica and other systemic inflammatory diseases.

Authors:  P Vaith; G M Hänsch; H H Peter
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

5.  Acute phase proteins, C9, factor B, and lysozyme in recurrent oral ulceration and Behçet's syndrome.

Authors:  T Lehner; M Adinolfi
Journal:  J Clin Pathol       Date:  1980-03       Impact factor: 3.411

6.  Humoral immunity against Francisella tularensis after natural infection.

Authors:  P Koskela; A Salminen
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

7.  A 28,000-dalton protein of normal mouse serum binds specifically to the inner core region of bacterial lipopolysaccharide.

Authors:  L Brade; H Brade
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system.

Authors:  H Jiang; T F Lint; H Gewurz
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

9.  Activation of platelets by modified C-reactive protein.

Authors:  B A Fiedel; R M Simpson; H Gewurz
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

10.  Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis.

Authors:  Waliza Ansar; Sumi Mukhopadhyay; S K Hasan Habib; Shyamasree Basu; Bibhuti Saha; Asish Kumar Sen; C N Mandal; Chitra Mandal
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.